Activation of endothelial nitric oxide synthase by a vanadium compound ameliorates pressure overload-induced cardiac injury in ovariectomized rats

Hypertension

Volumn 53, Issue 1, 2009, Pages 57-63

  Bhuiyan, Md Shenuarin ^a   Shioda, Norifumi ^a   Shibuya, Masatoshi ^a   Iwabuchi, Yoshiharu ^a   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Dystrophin; Endothelial nitric oxide synthase (eNOS); Myocardial hypertrophy; Ovariectomy; Protein kinase B (Akt)

Indexed keywords

BIS(1 OXY 2 PYRIDINETHIOLATO)OXOVANADIUM; CALPASTATIN; DYSTROPHIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOPRENALINE; MYOSIN LIGHT CHAIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE; CALCIUM BINDING PROTEIN; CARDIOTONIC AGENT; ENOS PROTEIN, RAT; INDUCIBLE NITRIC OXIDE SYNTHASE; OXOVANADIUM IV; VANADIC ACID;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA STENOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE DP-DT; HEART PROTECTION; HEART RATE; HEMODYNAMIC PARAMETERS; KAPLAN MEIER METHOD; MEAN ARTERIAL PRESSURE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; ANIMAL; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECT; ELECTROLYTE BALANCE; HEART CONTRACTION; HEART LEFT VENTRICLE HYPERTROPHY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; BLOOD PRESSURE; CALCIUM-BINDING PROTEINS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTROPHIN; FEMALE; HEART RATE; HYPERTROPHY, LEFT VENTRICULAR; ISOPROTERENOL; MYOCARDIAL CONTRACTION; NITRIC OXIDE SYNTHASE TYPE II; OVARIECTOMY; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; VANADATES; WATER-ELECTROLYTE BALANCE;

EID: 58149399356     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.118356     Document Type: Article

References (33)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Casteili WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
2. Luedde M, Katus HA, Frey N. Novel molecular targets in the treatment of cardiac hypertrophy. Recent Pal Cardiovasc Drug Discov. 2006; 1:1-20.
3. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein-kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
4. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000;101:660-667.
5. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, Rosenzweig A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001;104:330-335.
6. Kemi OJ, Celi M, Wisloff U, Grirnaldi S, Gallo P, Smith GL, Condorelli G, Ellingsen O. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J Cell Physiol. 2008;214:316-321.
7. Bhuiyan MS, Shioda N, Fukunaga K. Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats. Am J Physiol Endocrinol Metab. 2007;293:E1606-E1614.
8. 2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension. 2003;41:963-967.
9. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998;101:812-818.
10. Scherrer-Crosbie M, UMch R, Bloch KD, Nakajima H, Nassen B, Aretz HT, Lindsey ML, Vacon AC, Huang PL, Lee RT, Zapol WM, Picard MH. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation. 2001;104:1286-1291.
11. Linz W, Wohlfart P, Schölkens BA, Malinski T, Wiemer G. Interactions among ACE, kinins and NO. Cardiovasc Res. 1999;43:549-561.
12. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK. Stalins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429-1437.
13. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;105: 868-873.
14. Ogita H, Node K, Liao Y, Ishikura F, Beppu S, Asanuma H, Sanada S, Takashima S, Minamino T, Hori M, Kitakaze M. Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension. 2004;43:237-242.
15. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature (Land). 1999;399:601-605.
16. Fulton D, Gratton J-P, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature (Land). 1999; 399:597-601.
17. Takada Y, Hashimoto M, Kasahara J, Aihara K, Fukunaga K. Cytoprotective effect of sodium orthovanadate on ischemia/reperfusion-induced injury in rat Herat involves Akt activation and inhibition of fodrin breakdown and apoptosis. J Pharmacol Exp Ther. 2004;311:1249-1255.
18. Bhuiyan MS, Shibuya M, Shioda N, Moriguchi S, Kasahara J, Iwabuchi Y, Fukunaga K. Cytoprotective effect of bis(1-oxy-2-pyridinethiolato) oxovanadium(IV) on myocardial ischemia/reperfusion injury elicits inhibition of Fas ligand and Bim expression and elevation of FLIP expression. Eur J Pharmacol. 2007;571:180-188.
19. Bhuiyan MS, Takada Y, Shioda N, Moriguchi S, Kasahara J, Fukunaga K. Cardioprotective effect of vanadyl sulfate on ischemia/reperfusion-induced injury in rat heart in vivo is mediated by activation of protein kinase B and induction of FLICE-inhibitory protein. Cardiovasc Ther. 2008;26:10-23.
20. Liem DA, Gho CC, Gho BC, Kazim S, Manintveld OC, Verdouw DD, Duncker DJ. The tyrosine phosphotase inhibitor bis(maltolato)oxovanadium (IV) attenuates myocardial reperfusion injury by opening ATP-sensitive potassium channels. J Pharmacol Exp Ther. 2004;309: 1256-1262.
21. Shioda N, Ishigami T, Han F, Moriguchi S, Shibuya M, Iwabuchi Y, Fukunaga K. Activation of phophatidylinositol 3-kinase/protein kinase B pathway by a vanadyl compound mediates its neuroprotective effect in mouse brain ischemia. Neuroscience. 2007;148:221-229.
22. Geraldes CF, Castro MM, Sherry AD, Ramasamy R. Influence of Vanadate on glycolysis, intracellular sodium and pH in perfused rat hearts. Mol Cell Biochem. 1997;170:53-63.
23. Bhanot S, McNeill JH. Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension. 1994;24: 625-632.
24. Bhanot S, McNeill JH, Bryer-Ash M. Vanadyl sulfate prevents fructose-induced hyperinsulinemia and hypertension in rats. Hypertension. 1994; 23:308-312.
25. Bhanot S, Michoulas A, McNeill JH. Antihypertensive effects of vanadium compounds in hyperinsulinemic, hypertensive rats. Mol Cell Biochem. 1995;153:205-209.
26. Sakurai H, Sano H, Takino T, Yasui H. An orally active antidiabetic vanadyl complex, bis(1-oxy-2-pyridinethiolato)oxovanadium (IV), with VO(S2O2) coordination mode; in vitro and in vivo evaluations in rats. J Inorg Biochem. 2000;80:99-105.
27. Takeshita S, Kawamura I, Yasuno T, Kimura C, Yamamoto T, Seki J, Tamura A, Goto T. Amelioration of insulin resistance in diabetic ob/ob mice by a new type of rally active insulin-mimetic vanadyl complex: bis(1-oxy-2- pyridinethiolato)oxovanadium (IV), with VO(S2O2) coordination mode. J Inorg Biochem. 2001;85:179-186.
28. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, Bender JR. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3K-Akt pathway in human endothelial cells. Circ Res. 2000;87:677-682.
29. Zeng G, Nystrom Fh, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101:1539-1545.
30. Fulton D, Gratton J-P, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther. 2001;299:818-824.
31. Lu YM, Shioda N, Han F, Moriguchi S, Kasahara J, Shirasaki Y, Qin ZH, Fukunaga K. Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes. Biochem Pharmacol. 2007;74:1727-1737.
32. Condorelli G, Drasco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, Ross J Jr. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A. 2002;99:12333-12338.
33. Bhuiyan MS, Shioda N, Fukunaga K. Targeting protein kinase B/Akt signaling with vanadium compounds for cardioprotection. Expert Opin Ther Targets. 2008;12:1217-1227.